Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > SO IM MISSING THE GOOD NEWS
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1577)
•••
Comment by DJDawgon Aug 15, 2024 12:12pm
193 Views
Post# 36180783

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:SO IM MISSING THE GOOD NEWS

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:SO IM MISSING THE GOOD NEWS
What would be great is if the application got a boost from duration of response AFTER last treatment, maintenance event.

For Anktiva+BCG the protocol is such that you get 3, weekly maintenance instillations every 6months, ongoing. You finish the every 3m schedule at month 13 and then go to every 6m. So you never really have pure CR since last event since it never really stops.
 
For Adstiladrin, every 3months, ongoing I think. So never ends either.

Ruvidar is the only treatment that has a bunch of patients that are 1 yr from any intervention or longer.

Hopefully the FDA consultants that they have can guide them on how to emphasize this detail.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities